Navigation Links
GeoVax Labs, Inc. Information To Be Available Through Standard & Poor's Market Access Program
Date:10/1/2008

ATLANTA, Oct. 1 /PRNewswire-FirstCall/ -- GeoVax Labs, Inc. (OTC Bulletin Board: GOVX), an Atlanta biopharmaceutical company developing human vaccines for diseases caused by HIV-1 (Human Immunodeficiency Virus) and other infectious agents, announced today that its company information will be made available via Standard & Poor's Market Access Program, an information distribution service that enables subscribing publicly traded companies to have their company information disseminated to users of Standard & Poor's Advisor Insight. The company information to be made available through this program includes share price, volume, dividends, shares outstanding, company financial position, and earnings. Standard & Poor's Advisor Insight is an Internet-based research engine used by more than 100,000 investment advisors. A public version of the site is available at http://www.advisorinsight.com.

In addition, information about companies in Standard & Poor's Market Access Program will be available via S&P's Stock Guide database, which is distributed electronically to virtually all major quote vendors. As part of the program, a full description of GeoVax Labs, Inc. will also be published in the Daily News section of Standard Corporation Records, a recognized securities manual for secondary trading in approximately 38 states under their Blue Sky Laws.

About GeoVax Labs, Inc.

GeoVax Labs, Inc. is a biotechnology company, established to develop, manufacture, license and commercialize human vaccines for diseases caused by HIV-1 (Human Immunodeficiency Virus) and other infectious agents. GeoVax's AIDS vaccine technology is the subject of 20 issued or filed patent applications. GeoVax AIDS vaccines are designed for use in uninfected people to prevent Acquired Immunodeficiency Disease (AIDS), caused by the virus known as HIV-1, should the person ever become infected. GeoVax AIDS vaccines also may be effective as therapeutics, treatment of people already infected with AIDS virus.

GeoVax's core AIDS vaccine technologies were developed by Dr. Harriet Robinson, Senior V.P. of Research and Development, through a collaboration of colleagues at Emory University's Vaccine Center, the National Institutes of Health (NIH), The Centers for Disease Control and Prevention (CDC) and GeoVax.

GeoVax AIDS vaccines have moved forward in human clinical trials conducted by the HIV Vaccine Trials Network (HVTN) based in Seattle, Washington. The HVTN, funded through a cooperative agreement with the National Institutes of Health (NIH), is the largest worldwide clinical trials program dedicated to the development and testing of AIDS vaccines. Preclinical work enabling evaluation of GeoVax DNA and MVA vaccines was funded and supported by NIAID, which provided additional support to GeoVax AIDS vaccine development program with a $15 million IPCAVD grant awarded in late 2007.

Company information distributed through the Market Access Program is based upon information that Standard & Poor's considers to be reliable, but neither the Company nor Standard & Poor's or its affiliates warrant its completeness or accuracy, and it should not be relied upon as such. This material is not intended as an offer or solicitation for the purchase or sale of any security or other financial instrument.

For more information on GeoVax Labs, Inc. please visit our website at http://www.geovax.com.


'/>"/>
SOURCE GeoVax Labs, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. GeoVax Labs, Inc. Second Quarter Financial Results and Operational Update
2. U.S. Government Awards $15 Million Grant to GeoVax Labs HIV/AIDS Vaccine Program
3. GeoVax Further Strengthens Management Team
4. GeoVax Labs, Inc. Announces Six Month Financial Results and Provides Operational Update
5. ImmuneRegen Responds to Defense Threat Reduction Agency Request for Information
6. Updated NIH Guidelines Offer Valuable Information on Asthma Diagnosis and Management
7. Six UK Hospitals Join Together in Using Varian Medical Oncology Information Network
8. Thomson Scientific to Host Pharmaceutical Vision - A Users Conference for Information, Regulatory Affairs, Competitive Intelligence and Biotechnology Professionals
9. IFRS Information - First Half of 2007
10. Cephalon Reinforces Important Prescribing and Dosing Information for FENTORA
11. Researchers improve ability to write and store information on electronic devices
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... -- Research and Markets has announced the addition ... Markets and Companies" to their offering. ... , , ... genome variations, development of sequencing technologies, and their applications. Current ... developing them. Various applications of sequencing are described including those ...
(Date:12/4/2016)... Francisco, CA (PRWEB) , ... December 03, 2016 ... ... grants to ground-breaking microbiome studies. A microbiome impact grant award has been made ... the effect of heavy smoking and drinking on the oral microbiome. Grant proposals ...
(Date:12/2/2016)... ... , ... In anticipation of AxioMed’s exclusive cleanroom manufacturing facility ... Jake Lubinski will be traveling to Switzerland from December 5-10. Mr. Lubinski will ... Zurich to discuss the benefits of a viscoelastic disc. AxioMed received CE mark ...
(Date:12/2/2016)... 2016 Amgen (NASDAQ: AMGN ) and ... submission of a Marketing Authorization Application (MAA) to the European ... Avastin ® (bevacizumab). The companies believe this submission is ... "The submission of ABP 215 to the EMA ... oncology portfolio," said Sean E. Harper , M.D., executive ...
Breaking Biology Technology:
(Date:6/27/2016)... Research and Markets has announced the addition ... to their offering. The report ... to grow at a CAGR of 12.28% during the period 2016-2020. ... in-depth market analysis with inputs from industry experts. The report covers ... The report also includes a discussion of the key vendors operating ...
(Date:6/20/2016)... -- Securus Technologies, a leading provider of civil ... investigation, corrections and monitoring announced that after exhaustive ... the final acceptance by all three (3) Department ... (MAS) installed. Furthermore, Securus will have contracts for ... October, 2016. MAS distinguishes between legitimate wireless device ...
(Date:6/7/2016)... TORONTO , June 7, 2016  Syngrafii ... begun a business relationship that includes integrating Syngrafii,s ... pilot branch project. This collaboration will result in ... for the credit union, while maintaining existing document ... http://photos.prnewswire.com/prnh/20160606/375871LOGO ...
Breaking Biology News(10 mins):